Cargando…

High expression of UBD correlates with epirubicin resistance and indicates poor prognosis in triple-negative breast cancer

BACKGROUND: Triple-negative breast cancer (TNBC) is a heterogeneous subtype of breast cancer that is prone to recurrence and metastasis with worse prognosis. Epirubicin-based chemotherapy is of great importance for patients with TNBC, but resistance to epirubicin severely limits the application of t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Han, Tao, Liu, Zhaozhe, Li, Hengyu, Xie, Wanqing, Zhang, Ranran, Zhu, Li, Guo, Fang, Han, Yaling, Sheng, Yuan, Xie, Xiaodong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4500622/ https://www.ncbi.nlm.nih.gov/pubmed/26185453 http://dx.doi.org/10.2147/OTT.S81214

Ejemplares similares

SU6668 suppresses proliferation of triple negative breast cancer cells through down-regulating MTDH expression
por: Wang, Lu, et al.
Publicado: (2013)

Diubiquitin (Ubd) is a susceptibility gene for virus-triggered autoimmune diabetes in rats
por: Cort, Laura, et al.
Publicado: (2014)

Ubiquitin-Like Protein UBD Promotes Cell Proliferation in Colorectal Cancer by Facilitating p53 Degradation
por: Su, Hongbin, et al.
Publicado: (2021)

Small breast epithelial mucin tumor tissue expression is associated with increased risk of recurrence and death in triple-negative breast cancer patients
por: Liu, Liang, et al.
Publicado: (2013)

Ki67 as a predictor of poor prognosis in patients with triple-negative breast cancer
por: LI, HAITAO, et al.
Publicado: (2015)

Neoadjuvant Dose-Dense Gemcitabine plus Docetaxel and Vinorelbine plus Epirubicin for Operable Breast Cancer: Improved Prognosis in Triple-Negative Tumors
por: Medioni, Jacques, et al.
Publicado: (2012)

Low Expression of CLEC2B Indicates Poor Prognosis in Melanoma
por: Zhang, Yanqiu, et al.
Publicado: (2023)

Increased expression of OPN contributes to idiopathic pulmonary fibrosis and indicates a poor prognosis
por: Ji, Jie, et al.
Publicado: (2023)

Breast cancer metastasis to the stomach confirmed using gastroscopy: A case report
por: TAN, LINSHEN, et al.
Publicado: (2014)

Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer
por: Li, Qing, et al.
Publicado: (2020)

Expression of RUNX1 Correlates with Poor Patient Prognosis in Triple Negative Breast Cancer
por: Ferrari, Nicola, et al.
Publicado: (2014)

MAT2B expression correlates with poor prognosis in triple-negative breast cancer
por: Xu, Jin, et al.
Publicado: (2019)

High Expression of microRNA-223 Indicates a Good Prognosis in Triple-Negative Breast Cancer
por: Chen, Li, et al.
Publicado: (2021)

High Survivin and Low Zinc Finger of the Cerebellum 1 Expression Indicates Poor Prognosis in Triple-negative Breast Carcinoma
por: Shi, Chun-Tao, et al.
Publicado: (2019)

The implication from RAS/RAF/ERK signaling pathway increased activation in epirubicin treated triple negative breast cancer
por: Huang, Jianbo, et al.
Publicado: (2017)

Novel Long Noncoding RNA 005620 Induces Epirubicin Resistance in Triple-Negative Breast Cancer by Regulating ITGB1 Expression
por: Wang, Fengliang, et al.
Publicado: (2021)

Accumulation of p62 is associated with poor prognosis in patients with triple-negative breast cancer
por: Luo, Rong-Zhen, et al.
Publicado: (2013)

CD24 Overexpression Is Associated with Poor Prognosis in Luminal A and Triple-Negative Breast Cancer
por: Kwon, Mi Jeong, et al.
Publicado: (2015)

The expressions of NEDD9 and E-cadherin correlate with metastasis and poor prognosis in triple-negative breast cancer patients
por: Li, Peng, et al.
Publicado: (2016)

A CLDN1-Negative Phenotype Predicts Poor Prognosis in Triple-Negative Breast Cancer
por: Ma, Fei, et al.
Publicado: (2014)

Down-regulated FST expression is involved in the poor prognosis of triple-negative breast cancer
por: Liu, Sainan, et al.
Publicado: (2021)

CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer
por: Zhao, Zi-Ming, et al.
Publicado: (2019)

Epirubicin
por: Cornish, J., et al.
Publicado: (1988)

Self-Assembled Dual-Targeted Epirubicin-Hybrid Polydopamine Nanoparticles for Combined Chemo-Photothermal Therapy of Triple-Negative Breast Cancer
por: Li, Xiang, et al.
Publicado: (2020)

Patients with Concordant Triple-Negative Phenotype between Primary Breast Cancers and Corresponding Metastases Have Poor Prognosis
por: Shin, Hee-Chul, et al.
Publicado: (2016)

Elevation of CXCL1 indicates poor prognosis and radioresistance by inducing mesenchymal transition in glioblastoma
por: Alafate, Wahafu, et al.
Publicado: (2020)

Downregulation of the enhancer of zeste homolog 1 transcriptional factor predicts poor prognosis of triple-negative breast cancer patients
por: Peng, Wei, et al.
Publicado: (2022)

Inhibition of 6-Phosphogluconate Dehydrogenase Reverses Epirubicin Resistance Through Metabolic Reprograming in Triple-Negative Breast Cancer Cells
por: Xu, Jiali, et al.
Publicado: (2023)

High expression of microRNA-454 is associated with poor prognosis in triple-negative breast cancer
por: Cao, Zhi-Gang, et al.
Publicado: (2016)

circUSP42 Is Downregulated in Triple-Negative Breast Cancer and Associated With Poor Prognosis
por: Yu, Jinling, et al.
Publicado: (2020)

Low KIBRA Expression Is Associated with Poor Prognosis in Patients with Triple-Negative Breast Cancer
por: Kim, So-Woon, et al.
Publicado: (2021)

Integrated bioinformatic analysis of potential biomarkers of poor prognosis in triple-negative breast cancer
por: Bissanum, Rassanee, et al.
Publicado: (2022)

Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma
por: Li, Jing-ping, et al.
Publicado: (2019)

Comparison of Clinicopathological Features and Prognosis in Triple-Negative and Non-Triple Negative Breast Cancer
por: Qiu, Jingdan, et al.
Publicado: (2016)

Neoadjuvant camrelizumab plus nab-paclitaxel and epirubicin in early triple-negative breast cancer: a single-arm phase II trial
por: Wang, Chengzheng, et al.
Publicado: (2023)

TCOF1 upregulation in triple-negative breast cancer promotes stemness and tumour growth and correlates with poor prognosis
por: Hu, Jianyang, et al.
Publicado: (2021)

MTDH mediates trastuzumab resistance in HER2 positive breast cancer by decreasing PTEN expression through an NFκB-dependent pathway
por: Du, Cheng, et al.
Publicado: (2014)

CD44(+)/CD24(−) phenotype predicts a poor prognosis in triple-negative breast cancer
por: Wang, Hui, et al.
Publicado: (2017)

Cepharanthine sensitizes human triple negative breast cancer cells to chemotherapeutic agent epirubicin via inducing cofilin oxidation-mediated mitochondrial fission and apoptosis
por: Shen, Li-wen, et al.
Publicado: (2021)

Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
por: Li, Junjie, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_for07e8cqtao1be5gk1d52gcep